CN116593719A - FOB fecal occult blood and HP helicobacter pylori combined detection strip and detection method thereof - Google Patents
FOB fecal occult blood and HP helicobacter pylori combined detection strip and detection method thereof Download PDFInfo
- Publication number
- CN116593719A CN116593719A CN202310307528.2A CN202310307528A CN116593719A CN 116593719 A CN116593719 A CN 116593719A CN 202310307528 A CN202310307528 A CN 202310307528A CN 116593719 A CN116593719 A CN 116593719A
- Authority
- CN
- China
- Prior art keywords
- detection
- strip
- helicobacter pylori
- occult blood
- fecal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 126
- 210000004369 blood Anatomy 0.000 title claims abstract description 40
- 239000008280 blood Substances 0.000 title claims abstract description 40
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 38
- 230000002550 fecal effect Effects 0.000 title claims abstract description 38
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 38
- 238000003908 quality control method Methods 0.000 claims abstract description 17
- 239000000427 antigen Substances 0.000 claims abstract description 11
- 102000036639 antigens Human genes 0.000 claims abstract description 11
- 108091007433 antigens Proteins 0.000 claims abstract description 11
- 238000005070 sampling Methods 0.000 claims abstract description 9
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 5
- 230000000694 effects Effects 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 36
- 239000003153 chemical reaction reagent Substances 0.000 claims description 19
- 238000012360 testing method Methods 0.000 claims description 17
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 claims description 11
- 102000001554 Hemoglobins Human genes 0.000 claims description 10
- 108010054147 Hemoglobins Proteins 0.000 claims description 10
- 238000003317 immunochromatography Methods 0.000 claims description 3
- 230000001360 synchronised effect Effects 0.000 abstract description 3
- 101001018064 Homo sapiens Lysosomal-trafficking regulator Proteins 0.000 description 4
- 102100033472 Lysosomal-trafficking regulator Human genes 0.000 description 4
- 235000010703 Modiola caroliniana Nutrition 0.000 description 4
- 244000038561 Modiola caroliniana Species 0.000 description 4
- 238000009534 blood test Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000010340 saliva test Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 108050006227 Haem peroxidases Proteins 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- XSQUKJJJFZCRTK-NJFSPNSNSA-N UREA C 14 Chemical compound N[14C](N)=O XSQUKJJJFZCRTK-NJFSPNSNSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229910001448 ferrous ion Inorganic materials 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229950000184 urea c 14 Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/726—Devices
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to a FOB occult blood and HP helicobacter pylori combined detection strip and a detection method thereof, wherein the detection method comprises the following steps: s1, randomly inserting and sampling human excrement through a sample chromatographic zone at the end part of a detection strip, and then carrying out upward chromatography under the capillary effect; s2, after the detection strip stands for a period of time, whether the FOB fecal occult blood and the HP helicobacter pylori in the fecal sample are positive or not is judged through the color band change of the first detection area, the second detection area and the quality control area on the detection strip. The detection strip can realize synchronous detection of two antigens FOB and HP, and can display two detection results simultaneously after single fecal sample sampling, so that patients do not need invasive detection and non-invasive detection of medical institutions, and the home autonomous detection results are clear at a glance.
Description
Technical Field
The invention relates to the field of biomedical detection, in particular to a FOB fecal occult blood and HP helicobacter pylori combined detection strip and a detection method thereof.
Background
When the human body is detected healthily, helicobacter pylori detection and fecal occult blood detection are involved, and the helicobacter pylori detection modes comprise:
1. blood drawing examination: this method is mainly to judge helicobacter pylori infection by checking the amount of helicobacter pylori antibodies by blood drawing, and is generally inaccurate. Since helicobacter pylori is colonized on the surface of the gastric mucosa, it is generally not available to the blood, and after healing, the patient remains in the blood for 1 to 2 years with helicobacter pylori antibodies, during which time false positive results occur when blood is drawn.
2. C13 and C14 urea breath test: because C14 pollutes human body and environment, the isotope can not be degenerated in human body (6 ten thousand years in the whole degenerated period) after taking, so the method is not suitable for pregnant women and children. C13 is non-radioactive and does not pollute the environment, and the method needs to take corresponding C13 marked urea, but can not take medicines such as stomach and the like to medical institutions for empty stomach and within a week.
3. Saliva detection method: the saliva test board is used for detecting the humor antigen indirectly, and the urease sensitivity and specificity are measured, but the detection needs to be completed by a professional medical institution.
4. Gastroscope and gastric mucosa biopsy: the method is characterized in that the accuracy of histological examination pathological section is high, the accuracy of quick urease test chemical reaction is low, and because the method belongs to an invasive mode, helicobacter pylori in the stomach is distributed in a focus shape, and the mucous membrane part possibly taken is free of bacteria, miss diagnosis, cause false negative and have high cost, some patients are relatively exclusive, and the method is not suitable for general investigation.
In summary, helicobacter pylori detection mainly includes both invasive and non-invasive tests. Blood sampling tests, C13 and C14 breath tests, saliva tests are non-invasive tests, while gastroscopy and gastric mucosal biopsies are invasive tests.
The fecal occult blood test (FOB) is a test in which blood is carried in the feces when the amount of hemorrhage in the digestive tract is small, and a small amount of red blood cells in the feces are destroyed, and the test can be only performed by a chemical or immunological method, and the test method of the fecal occult blood test includes:
1. the traditional method comprises the following steps: method for reducing phenolphthalein benzidine method, o-toluidine method, colorless malachite green method, guaiacyl ester method and Piramide hole method
2. An immunization method;
3. hemoglobin detection method (FOB) -detecting hemoglobin (Hb) in feces;
4. transferrin detection method- -a chemical method for detecting transferrin in feces 2.1;
5. conventional method
Principle of: the heme peroxidase activity in the hemoglobin can catalyze hydrogen peroxide, emit nascent oxygen, oxidize acceptor reagent and develop color.
The advantages are that: the results showed fast and clear, and the results could be semi-quantitative.
Disadvantages: A. poor specificity and is greatly affected by diet. Food and drugs containing ferrous ions interfere with the results and the false positive rate is 30%. Before the occult blood test, the patient is instructed to avoid taking iron, animal blood, liver, lean meat and a large amount of green leaf vegetables for 3 days, such as gingival bleeding, and not to swallow blood saliva, so as to prevent the fecal occult blood test from being false positive.
B. The sensitivity is low, and the bleeding amount is more than 90 mug/ml.
C. The methodological constraints are as follows: the patient is prepared for a long time in advance. Because of different material-drawing parts, different reaction time and different judgment on color development, errors can also be generated in the test of the same method.
Moreover, at present, no means and method for synchronously detecting the foetus occult blood and the HP helicobacter pylori are available, and the patent designs a method for carrying out joint detection on the foetus occult blood and the HP helicobacter pylori based on the existing technical problems.
Disclosure of Invention
The invention aims to solve the defects in the prior art and provides a FOB fecal occult blood and HP helicobacter pylori combined detection strip and a detection method thereof.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
the FOB fecal occult blood and HP helicobacter pylori combined detection strip consists of a sample chromatographic zone, a reagent part and an unfolding part;
the sample chromatographic zone is positioned at the end part of the detection strip, the reagent part is connected with the sample chromatographic zone, and the unfolding part is connected with the reagent part;
the unfolding part is provided with a first detection area, a second detection area and a quality control area.
A detection method of a FOB occult blood and HP helicobacter pylori combined detection strip comprises the following steps:
s1, randomly inserting and sampling human excrement through a sample chromatographic zone at the end part of a detection strip, and then carrying out upward chromatography under the capillary effect;
s2, after the detection strip stands for a period of time, whether the FOB fecal occult blood and the HP helicobacter pylori in the fecal sample are positive or not is judged through the color band change of the first detection area, the second detection area and the quality control area on the detection strip.
If a purple red strip appears in the first detection area, the detection result is that the FOB occult blood is positive, the fecal sample contains human hemoglobin, otherwise, the detection result is that the FOB occult blood is negative;
if a purple red strip appears in the second detection area, the detection result is positive for HP helicobacter pylori, the fecal sample contains fecal HP antigen, otherwise, the detection result is negative for HP helicobacter pylori;
the mauve band appears in the quality control zone regardless of whether human hemoglobin and/or fecal HP antigen is present in the fecal sample.
The purplish red band appearing in the quality control area is a standard for judging whether enough samples exist or not and whether the chromatography process is normal or not, and is also used as an internal control standard of the reagent.
The outside of the detection strip is provided with a shell, the shell is provided with a display window, and the first detection area, the second detection area and the quality control area are displayed through the display window.
The detection reagent of the reagent part adopts a monoclonal antibody technology and an immunochromatography technology, specifically a colloidal gold and latex method, and the detection principle is a double-antibody sandwich method.
The beneficial effects of the invention are as follows: the detection strip can realize synchronous detection of two antigens FOB and HP, and after single fecal sample sampling, the detection strip can display two detection results simultaneously, so that patients do not need invasive detection and non-invasive detection of medical institutions, and the home autonomous detection results are clear at a glance;
moreover, the invention adopts the method of detecting by using the gold and latex, thereby being more accurate and effective; the embarrassment of queuing and sampling in hospitals is avoided in home detection; the operation is simple and rapid, only a few steps are needed, and the detection result is obtained within 5-10 minutes.
Drawings
FIG. 1 is a graph showing the results of the test strips when FOB shows positive occult blood and HP has negative helicobacter pylori;
FIG. 2 is a graph showing the results of the test strips when HP helicobacter pylori is positive and FOB occult blood is negative;
FIG. 3 is a graph showing the results of the test strips when FOB is positive for occult blood and HP helicobacter pylori;
FIG. 4 is a graph showing the results of the test strips when FOB is negative for occult blood and HP helicobacter pylori;
FIG. 5 is a graph showing the results of a test strip detection when it is not valid;
FIG. 6 is a graph showing another display of test strip detection invalidity.
Detailed Description
The FOB fecal occult blood and HP helicobacter pylori combined detection strip consists of a sample chromatographic zone 1, a reagent part 2 and an unfolding part 3;
the sample chromatographic zone 1 is positioned at the end part of the detection strip, the reagent part 2 is connected with the sample chromatographic zone 1, and the unfolding part 3 is connected with the reagent part 2;
the unfolding part 3 is provided with a first detection area A, a second detection area B and a quality control area C, a shell is arranged outside the detection strip, a display window is arranged on the shell, and the first detection area A, the second detection area B and the quality control area C are displayed through the display window.
The detection method of the FOB occult blood and HP helicobacter pylori combined detection strip specifically comprises the following steps:
s1, randomly inserting and sampling human excrement through a sample chromatographic zone 1 at the end part of a detection strip, and then carrying out upward chromatography under the capillary effect;
s2, after the detection strip stands for a period of time, whether FOB in the fecal sample is positive to occult blood and HP helicobacter pylori is judged through the color band change of the first detection area A, the second detection area B and the quality control area C on the detection strip.
As shown in fig. 1, a purple red band appears in the first detection area a, the detection result is positive for the FOB occult blood, the fecal sample contains human hemoglobin, otherwise, the detection result is negative for the FOB occult blood;
as shown in FIG. 2, a purple red strip appears in the second detection zone B, the detection result is positive for HP helicobacter pylori, the fecal sample contains fecal HP antigen, otherwise, the detection result is negative for HP helicobacter pylori;
as shown in FIG. 3, the first detection zone A has a purple red band, the second detection zone B has a purple red band, the detection result is that FOB is positive in occult blood, the fecal sample contains human hemoglobin, the detection result is that HP helicobacter pylori is positive, and the fecal sample contains fecal HP antigen.
As shown in FIG. 4, the first detection zone A and the second detection zone B have no mauve band, and when the quality control zone C has a mauve band, the detection result is that FOB is negative in occult blood and HP helicobacter pylori is negative.
As shown in fig. 5 and 6, no matter whether human hemoglobin and/or fecal HP antigen exist in fecal samples, mauve bands appear in quality control zone C, otherwise, the detection result is invalid.
The purple red band appearing in the quality control region C is a standard for judging whether a sufficient sample exists or not, and whether the chromatographic process is normal or not, and is also used as an internal control standard of the reagent.
The detection reagent of the reagent part adopts a monoclonal antibody technology and an immunochromatography technology, specifically a colloidal gold and latex method, and the detection principle is a double-antibody sandwich method.
The detection strip can realize synchronous detection of two antigens FOB and HP, and after single fecal sample sampling, the detection strip can display two detection results simultaneously, so that patients do not need invasive detection and non-invasive detection of medical institutions, and the home autonomous detection results are clear at a glance;
moreover, the invention adopts the method of detecting by using the gold and latex, thereby being more accurate and effective; the embarrassment of queuing and sampling in hospitals is avoided in home detection; the operation is simple and rapid, only a few steps are needed, and the detection result is obtained within 5-10 minutes.
The foregoing has shown and described the basic principles, principal features and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, and that the above embodiments and descriptions are merely illustrative of the principles of the present invention, and various changes and modifications may be made therein without departing from the spirit and scope of the invention, which is defined by the appended claims. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (8)
1. The FOB fecal occult blood and HP helicobacter pylori combined detection strip is characterized by comprising a sample chromatographic zone, a reagent part and an unfolding part;
the sample chromatographic zone is positioned at the end part of the detection strip, the reagent part is connected with the sample chromatographic zone, and the unfolding part is connected with the reagent part;
the unfolding part is provided with a first detection area, a second detection area and a quality control area.
2. A detection method of a FOB occult blood and HP helicobacter pylori combined detection strip is characterized by comprising the following steps:
s1, randomly inserting and sampling human excrement through a sample chromatographic zone at the end part of a detection strip, and then carrying out upward chromatography under the capillary effect;
s2, after the detection strip stands for a period of time, whether the FOB fecal occult blood and the HP helicobacter pylori in the fecal sample are positive or not is judged through the color band change of the first detection area, the second detection area and the quality control area on the detection strip.
3. The method of claim 2, wherein if a purple red band appears in the first detection zone, the detection result is positive for the foetus-occult blood, and the faecal sample contains human hemoglobin, otherwise, the detection result is negative for the foetus-occult blood.
4. The method according to claim 2, wherein if a purple red band appears in the second detection zone, the detection result is positive for HP helicobacter pylori, and the fecal sample contains fecal HP antigen, otherwise, the detection result is negative for HP helicobacter pylori.
5. The method of claim 2, wherein the purple-red band is present in the quality control zone regardless of whether human hemoglobin and/or fecal HP antigen is present in the fecal sample.
6. The method according to claim 5, wherein the purple red band appearing in the quality control region is a criterion for judging whether there is a sufficient sample and whether the chromatographic process is normal, and is also used as an internal control criterion for the reagent.
7. The method for detecting the combined detection strip of the foetus occult blood and the HP helicobacter pylori according to claim 5, wherein a shell is arranged outside the detection strip, a display window is arranged on the shell, and the first detection area, the second detection area and the quality control area are displayed through the display window.
8. The method for detecting a combined test strip of foetus occult blood and HP helicobacter pylori according to claim 5, wherein the detection reagent of the reagent section adopts a monoclonal antibody technique and an immunochromatography technique.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310307528.2A CN116593719A (en) | 2023-03-27 | 2023-03-27 | FOB fecal occult blood and HP helicobacter pylori combined detection strip and detection method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310307528.2A CN116593719A (en) | 2023-03-27 | 2023-03-27 | FOB fecal occult blood and HP helicobacter pylori combined detection strip and detection method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116593719A true CN116593719A (en) | 2023-08-15 |
Family
ID=87588730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310307528.2A Pending CN116593719A (en) | 2023-03-27 | 2023-03-27 | FOB fecal occult blood and HP helicobacter pylori combined detection strip and detection method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116593719A (en) |
-
2023
- 2023-03-27 CN CN202310307528.2A patent/CN116593719A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhu et al. | Using a glucose meter to quantitatively detect disease biomarkers through a universal nanozyme integrated lateral fluidic sensing platform | |
| JP2003533680A (en) | Reverse isotope dilution assay and lactose intolerance assay | |
| CN107328927B (en) | Combined detection kit for helicobacter pylori and gastrointestinal hemorrhage and application method thereof | |
| Moayyedi et al. | Do patients need to fast for a 13C-urea breath test? | |
| CN110361547A (en) | The reagent and its detection method of a kind of chemiluminescence quantitative detection fecal occult blood and its detection lower digestive tract health purposes | |
| CN118067993B (en) | Combined detection kit for intestinal polyp detection, and preparation method, detection method and application thereof | |
| Cox et al. | Measurement of small intestinal permeability markers, lactulose, and mannitol in serum (results in celiac disease) | |
| CN117250352B (en) | Pepsin detection kit | |
| CN107356740A (en) | A kind of aptamer of cortisol and the gold label test strip for detecting cortisol | |
| EP0821238A2 (en) | Method and kit for confirming in vitro the diagnosis of the coeliac disease | |
| CN116593719A (en) | FOB fecal occult blood and HP helicobacter pylori combined detection strip and detection method thereof | |
| CN115267208B (en) | Antigen and kit for detecting helicobacter pylori antibody and preparation method thereof | |
| CN202383143U (en) | Antibody collaurum detection kit for helicobacter pylori | |
| US5348860A (en) | Screening test and kit for cancerous and precancerous conditions | |
| JPS62251663A (en) | Expiration inspection method without damaging body for measuring urease activity of stomach and section in vicinityof stomach by using isotope and material available for said inspection | |
| CN108414742A (en) | Pepsinogen I and pepsinogen I I combined detection kits and preparation method thereof and detection method | |
| Anania et al. | Breath tests in pediatrics | |
| Peredy et al. | Bedside diagnostic testing of body fluids | |
| ES2208099B1 (en) | EMPLOYMENT OF 4-GALACTOSIL-XYLOSA IN HUMANS FOR THE IN VIVO ASSESSMENT OF INTESTINAL LACTASE AS A NON-INVASIVE DIAGNOSTIC TEST OF THE DEFICIENCY OF THIS ENZYME. | |
| Kim et al. | A qualitative agar gel immunoprecipitin (IP) test for detection of fecal occult human hemoglobin | |
| Segen et al. | The patient's guide to medical tests: everything you need to know about the tests your doctor orders | |
| CN116718775B (en) | Composition, test paper and method for detecting colorectal cancer | |
| Ruffin et al. | Radioisotopes as Diagnostic Aids in Gastroenterology: An Evaluation | |
| Ridley et al. | Miscellaneous Laboratory Analyses/Gastric Fluid | |
| Gässler et al. | Urine and stool analyses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |